MEDFORD, Mass.--ArQule, a publicly held computational chemistry company here, announced it will collaborate with privately held Acadia Pharmaceuticals of San Diego, Calif., on the discovery and development of novel drug candidates.
The collaboration will combine ArQule's Mapping Array program with Acadia's high-throughput Receptor Selection and Amplification Technology--an ultra-high-throughput platform for cell-based functional analysis of signaling genes--for screening a number of drug candidates.